TELO
Telomir Pharmaceuticals, Inc.Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
- InstitutionsBULLISH
Q2 2026: 4 added (0 new), 0 trimmed or exited.
- AnalystsBULLISH
6 of 7 rate it Buy or better. Every target is above the price.
- TrendDOWNTREND
12% below its 50-day average.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | ADD | $2.1M |
| GEODE CAPITAL MANAGEMENT, LLC | ADD | $433.9K |
| VANGUARD FIDUCIARY TRUST CO | ADD | $288.4K |
| NORTHERN TRUST CORP | ADD | $78.8K |
| UBS Group AG | TRIM | $12.0K |
| OSAIC HOLDINGS, INC. | ADD | $44.9K |
| UBS Group AG | NEAR_EXIT | $18.7K |
| JANE STREET GROUP, LLC | TRIM | $15.5K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
7 analystsPrice is below the lowest target. Median implies +300%.Targets as of Oct 27, 2026.
| Date | Firm | Rating |
|---|---|---|
| Sep 17, 2026 | Maxim Group INITIATE | Buy |
Insider ledger
Form 4| Date | Insider | Type | Value |
|---|---|---|---|
| May 21, 2026 | Whalen Matthew Pratt Director | TO ISSUER | 25,000 sh |
| May 21, 2026 | Whalen Matthew Pratt Director | AWARD | 25,000 sh |
| May 21, 2026 | Del Giudice Matthew Paul Director | AWARD | 25,000 sh |
| May 21, 2026 | Del Giudice Matthew Paul Director | TO ISSUER | 25,000 sh |
| May 21, 2026 | MacPherson Edward Clouston Director | AWARD | 25,000 sh |
| May 21, 2026 | MacPherson Edward Clouston Director | TO ISSUER | 25,000 sh |
| May 21, 2026 | Aminov Erez CEO and Chairman | TO ISSUER | 2,000,000 sh |
| May 21, 2026 | Aminov Erez CEO and Chairman | AWARD | 1,960,170 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.03 | -$0.03–-$0.03 | — | $0.00 |
| Next Q | -$0.03 | -$0.03–-$0.03 | — | $0.00 |
| Current FY | -$0.11 | -$0.11–-$0.11 | — | $0.00 |
| Next FY | -$0.17 | -$0.17–-$0.17 | — | $0.00 |
Short side
FINRA· Oct 15, 2026SecBot reports
8 filings · 1 press release · 0 bullish · 0 bearish · 1 mixed · 7 neutral- NEUTRAL 8-KOct 6, 2026
Telomir Pharmaceuticals closed a ~$5.6M PIPE financing on October 5, 2026, issuing 4,843,300…
The PIPE provides near-term cash runway to fund the Phase 1/2 TNBC trial start, but the ~$5.6M is modest for a clinical-stage biotech. Monitor for the filing of the resale registration statement…
- NEUTRAL 8-KSep 17, 2026
Telomir Pharmaceuticals announced the peer-reviewed publication of preclinical data showing its…
Preclinical data in AMD is scientifically supportive of the platform's mechanism but does not change the near-term clinical catalyst — the Phase 1/2 TNBC trial. Monitor for patient enrollment…
- NEUTRAL PRESS RELEASESep 17, 2026
Telomir Pharmaceuticals published peer-reviewed preclinical data showing Telomir-Zn improved…
Monitor for enrollment updates or initial data from the Phase 1/2 TNBC trial, which is the primary near-term catalyst. The AMD data is exploratory and does not change the clinical or regulatory…
- NEUTRAL 8-KSep 14, 2026
Telomir Pharmaceuticals announced preclinical in-vitro data from Ohio State University showing…
This is a pipeline-expansion signal with no near-term revenue or clinical data catalyst. Monitor for any in vivo study initiation announcement or TNBC enrollment updates, which would be more…
All TELO filing & press-release reports (9)
- 8-K reportOct 6, 2026
- 8-K reportSep 17, 2026
- PRESS-RELEASE reportSep 17, 2026
- 8-K reportSep 14, 2026
- DEFA14A reportAug 19, 2026
- 8-K reportAug 10, 2026
- 8-K reportJun 15, 2026
- 8-K reportJun 8, 2026
- 8-K reportApr 24, 2026